Cargando…

Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain

Antisense oligonucleotides (AONs) are versatile molecules that can be used to modulate gene expression by binding to RNA. The therapeutic potential of AONs appears particularly high in the central nervous system, due to excellent distribution and uptake in brain cells, as well as good tolerability i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toonen, Lodewijk J.A., Casaca-Carreira, João, Pellisé-Tintoré, Maria, Mei, Hailiang, Temel, Yasin, Jahanshahi, Ali, van Roon-Mom, Willeke M.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899290/ https://www.ncbi.nlm.nih.gov/pubmed/29565739 http://dx.doi.org/10.1089/nat.2017.0705

Ejemplares similares

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
por: Toonen, Lodewijk J.A., et al.
Publicado: (2017)

Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3
por: Toonen, Lodewijk J. A., et al.
Publicado: (2016)

Solid-Phase Synthesis of Boranophosphate/Phosphorothioate/Phosphate Chimeric Oligonucleotides and Their Potential as Antisense Oligonucleotides
por: Takahashi, Yuhei, et al.
Publicado: (2021)

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
por: Koller, Erich, et al.
Publicado: (2011)

Controlled sulfur-based engineering confers mouldability to phosphorothioate antisense oligonucleotides
por: Genna, Vito, et al.
Publicado: (2023)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties
por: Miroshnichenko, S. K., et al.
Publicado: (2019)

Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies
por: Evers, Melvin M., et al.
Publicado: (2013)

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
por: Goyenvalle, Aurélie, et al.
Publicado: (2023)

Coexistence of Gait Disturbances and Chorea in Experimental Huntington's Disease
por: Casaca-Carreira, João, et al.
Publicado: (2015)

Transependymal Cerebrospinal Fluid Flow: Opportunity for Drug Delivery?
por: Casaca-Carreira, João, et al.
Publicado: (2017)

Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide
por: Evers, Melvin M., et al.
Publicado: (2011)

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017)

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
por: Synofzik, Matthis, et al.
Publicado: (2022)

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
por: Buijsen, Ronald A.M., et al.
Publicado: (2019)

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
por: Seth, Punit P, et al.
Publicado: (2012)

Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile
por: Hegarty, John P, et al.
Publicado: (2016)

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
por: Østergaard, Michael E, et al.
Publicado: (2020)

Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment
por: Arrico, Lorenzo, et al.
Publicado: (2022)

Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
por: Wan, W. Brad, et al.
Publicado: (2014)

Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity
por: Liang, Xue-Hai, et al.
Publicado: (2016)

Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2017)

Accessible light-controlled knockdown of cell-free protein synthesis using phosphorothioate-caged antisense oligonucleotides
por: Hartmann, Denis, et al.
Publicado: (2023)

Electronic Structures of LNA Phosphorothioate Oligonucleotides
por: Bohr, Henrik G., et al.
Publicado: (2017)

Phosphorothioate modified oligonucleotide–protein interactions
por: Crooke, Stanley T, et al.
Publicado: (2020)

Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection
por: Byrnes, Amy E., et al.
Publicado: (2023)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
por: Heemskerk, Hans, et al.
Publicado: (2010)

Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver
por: Miller, Colton M., et al.
Publicado: (2016)

Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Therapy with 2′-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption
por: Janssen, Manoe J., et al.
Publicado: (2019)

Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features
por: Hagedorn, Peter H., et al.
Publicado: (2022)

Antisense Oligonucleotide-Induced Amyloid Precursor Protein Splicing Modulation as a Therapeutic Approach for Dutch-Type Cerebral Amyloid Angiopathy
por: Daoutsali, Elena, et al.
Publicado: (2021)

Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes
por: Tanowitz, Michael, et al.
Publicado: (2017)

Selective Covalent Conjugation of Phosphorothioate DNA Oligonucleotides with Streptavidin
por: Rabe, Kersten S., et al.
Publicado: (2011)

Investigation of factors influencing the separation of diastereomers of phosphorothioated oligonucleotides
por: Enmark, Martin, et al.
Publicado: (2019)

Oligonucleotide Phosphorothioates Enter Cells by Thiol‐Mediated Uptake
por: Laurent, Quentin, et al.
Publicado: (2021)

G-rich motifs within phosphorothioate-based antisense oligonucleotides (ASOs) drive activation of FXN expression through indirect effects
por: Wang, Feng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o83q4aapp9aakb2rvc22i1u01h